Page last updated: 2024-12-05

fluocinolone acetonide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6215
CHEMBL ID989
CHEBI ID31623
SCHEMBL ID4795
MeSH IDM0008592

Synonyms (209)

Synonym
AC-429
MLS001076276 ,
NSC92339 ,
67-73-2
fluocinolone acetonide
localyn
NCI60_042042
fluonid
synandone
component of neo-synalar
percutina
difluoro-hydroxy-(2-hydroxyacetyl)-tetramethyl-[?]one
rs-1401 at
flupollon
sinalar
fluocinolone 16,17-acetonide
synsac
radiocin
6.alpha., 9.alpha.-difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide
synotic
synemol
synalar
synandrone
6.alpha.,9-difluoro
tefunote
jellin
omniderm
4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
dermalar
synamol
flucinar
fluovitif
coriphate
nsc-92339
6.alpha.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
pregna-1,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)-, (6.alpha.,11.beta.,16.alpha.)-
synalar-hp
pregna-1,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-
pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-
6.alpha.,17-acetonide
wln: t f5 e5 b666 go io rv ahtttt&j a bf cq e fviq h h of -a&bho -b&acef
localyn syntex
pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
einecs 200-668-5
6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
prodermin
ccris 3250
fluocinoloni acetonidum [inn-latin]
hsdb 3083
acetonida de fluocinolona [inn-spanish]
cortiplastol
fluocinolonacetonidum
6-alpha,9-alpha-difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide
fluotrex
rs 1401at
dermatin (steroid)
nsc 92339
fluortriamcinolone acetonide
fluocet
derma-smoothe/fs
fluocinolone acetonide [dcit]
retisert
acetonide de fluocinolone [inn-french]
fs shampoo
pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-
fluzon
6alpha,9alpha-difluoro-16alpha-hydroxyprednisolone 16,17-acetonide
DB00591
NCGC00021301-04
6alpha-fluorotriamcinolone acetonide
retisert (tn)
fluocet (tn)
D01825
fluocinolone acetonide (jp17/usp/inn)
synalar (tn)
MLS000028545 ,
smr000058329
(4as,4br,5s,6as,6bs,9ar,10as,10bs,12s)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
HMS2090I14
6alpha,9alpha-difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-acetonide
F0657 ,
chebi:31623 ,
CHEMBL989
oto-synalar
flucinolone acetonide
fluocinolide (acetate)
HMS3259G12
acetonide, fluocinolone
acetonide, fluortriamcinolone
capex
tox21_302364
cas-67-73-2
dtxcid8020674
dtxsid0040674 ,
NCGC00255654-01
tox21_110869
HMS2230D13
AKOS015963144
iluvien
fluocinoloni acetonidum
fluzon [steroid]
acetonida de fluocinolona
unii-0cd5fd6s2m
fluocinolone acetonide intravitreal implant
fluocinolone acetonide [usan:usp:inn:jan]
acetonide de fluocinolone
0cd5fd6s2m ,
fluocinolone acetonide [usp impurity]
fluocinolone acetonide [inn]
fluocinolone acetonide [usp-rs]
neo-synalar component fluocinolone acetonide
yutiq
fluocinolone acetonide [ep monograph]
fluocinolone acetonide component of iluvien
fluocinolone acetonide [orange book]
fluocinolone acetonide [usan]
fluocinolone acetonide [who-dd]
fluocinolone acetonide [vandf]
fluocinolone acetonide [mi]
fluocinolone acetonide [usp monograph]
fluocinolone acetonide [mart.]
fluocinolone acetonide [green book]
tri-luma component fluocinolone acetonide
fluocinolone acetonide [hsdb]
dermotic
fluocinolone acetonide component of neo-synalar
fluocinolone acetonide component of otovel
pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6.alpha.,11.beta.,16.alpha.)-
fluocinolone acetonide [jan]
fluocinolone acetonide component of tri-luma
otovel component fluocinolone acetonide
iluvien component fluocinolone acetonide
otovel component of fluocinolone acetonide
S2470
gtpl7077
CCG-221165
HY-B0415
fluocinolone (acetonide)
NC00562
FEBLZLNTKCEFIT-VSXGLTOVSA-N
SCHEMBL4795
tox21_110869_1
NCGC00021301-06
AB00383017-10
(4as,4br,5s,6as,6bs,9ar,10as,10bs,12s)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
acetonido de fluocinolona
W-104704
AB00383017_11
OPERA_ID_1295
(1s,2s,4r,8s,9s,11s,12r,13s,19s)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
flucort-n
SR-01000000109-2
sr-01000000109
fluocinolone acetonide, united states pharmacopeia (usp) reference standard
fluocinolone acetonide, european pharmacopoeia (ep) reference standard
fluocinolone acetonide, analytical standard
(2s,6as,6br,7s,8as,8bs,11ar,12as,12bs)-2,6b-difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2h)-one
fluocinolone acetonide for system suitability, european pharmacopoeia (ep) reference standard
fluocinolone acetonide, pharmaceutical secondary standard; certified reference material
fluocinolone acetonide for peak identification, european pharmacopoeia (ep) reference standard
HMS3715J11
fluocinolone acetonide (anti-inflammatory)
fluocinoloneacetonide
fluocinolone acetonide (flucort-n)
AS-13690
Q924467
BRD-K94353609-001-21-6
AC1069
(6alpha,11beta,16alpha)-6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
fluocinolone-acetonide
fluocinolone acetonide; 6?,9-difluoro-11?,21-dihydroxy-16?,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione
A853087
(6a,11b,16a)-6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione
fluocinolone acetonide for system suitability
fluocinolone acetonide - bp
BF176452
EN300-7410632
fluocinolone acetonide (usan:usp:inn:jan)
flac
fluocinolone acetonide (ep monograph)
(6alpha,11beta,16alpha)-6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))pregna-1,4-diene-3,20-dione
fluzon (steroid)
synalar solution veterinary
fluocinolone (alcohol)
fluocinolone acetonide (mart.)
fluocinolone acetonide (usp-rs)
fluocinonide acetonide
s01ba15
acetonide de fluocinolone (inn-french)
6alpha,9-difluoro-11beta,21-dihydroxy-16alpha,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione
(4as,4br,5s,6as,6bs,9ar,10as,10bs,12s)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho(2',1':4,5)indeno(1,2-d)(1,3)dioxol-2-one
d07ac04
fluocinolone acetonideoil
s02ba08
synalar cream veterinary
fluocinoloni acetonidum (inn-latin)
fluocinolone acetonide (usp impurity)
fluocinolone acetonide oil, 0.01% (ear drops)
fluocinolone acetonide topical solution usp, 0.01%
acetonida de fluocinolona (inn-spanish)
fluocinolone acetonide topical
xilapak
synalar ts
c05aa10
flac otic oil
fluocinolone acetonide (usp monograph)
fluocinolone acetonide 0.01%
fluocinolon acetonid

Research Excerpts

Overview

Fluocinolone acetonide (FAc) is an intravitreal corticosteroid implant approved for the second-line treatment of diabetic macular edema (DME) The drug is a potent topical glucocorticoid used in the treatment of skin disorders and oral lesions that could possibly be used to resolve inflammation.

ExcerptReferenceRelevance
"Fluocinolone acetonide is a valid alternative treatment for patients with chronic diabetic macular edema (DME) with poor response to anti-vascular endothelial growth factor (VEGF) therapy. "( Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data.
Avogaro, F; Calandri, A; Florido, A; Toja, F; Vingolo, EM, 2023
)
2.68
"Fluocinolone acetonide (FAc) is an intravitreal corticosteroid implant approved for the second-line treatment of diabetic macular edema (DME). "( Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Busch, C; Jochmann, C; Rehak, M; Unterlauft, JD; Wiedemann, P, 2020
)
2.22
"Fluocinolone acetonide implant is a valuable option in the treatment of persistent macular edema associated with JIA-related uveitis refractory to systemic treatments."( Fluocinolone acetonide intravitreal implant (Retisert
Immonen, I; Kotaniemi, K; Leinonen, S, 2018
)
3.37
"Fluocinolone acetonide is a potent topical glucocorticoid used in the treatment of skin disorders and oral lesions that could possibly be used to resolve inflammation and stimulate the healing process of inflamed dental pulp."( Effect of fluocinolone acetonide on human dental pulp cells: cytotoxicity, proliferation, and extracellular matrix formation.
Lertchirakarn, V; Louwakul, P; Muincharern, W; Pavasant, P, 2011
)
1.49
"Fluocinolone acetonide cream is a new, potent topical corticosteroid. "( Clinical studies with topical fluocinolone acetonide in the treatment of various dermatoses.
KANEE, B, 1963
)
1.97
"Fluocinolone acetonide gel 0.1% is a safe and effective alternative therapy to fluocinolone acetonide in an oral base 0.1% in the treatment of oral lichen planus."( Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus.
Buajeeb, W; Kraivaphan, P; Pobrurksa, C, 2000
)
2.13

Effects

Fluocinolone acetonide (FA) has been recently identified as a potential candidate for protection from PIPN. FA has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO.

ExcerptReferenceRelevance
"Fluocinolone acetonide (FA) has been recently identified as a potential candidate for protection from PIPN."( Fluocinolone Acetonide Enhances Anterograde Mitochondria Trafficking and Promotes Neuroprotection against Paclitaxel-Induced Peripheral Neuropathy.
Albin, B; Tiwari, AP; Tristan, LJC; Yang, IH, 2023
)
3.07
"A fluocinolone acetonide implant has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO."( Emerging therapies in the management of macular edema: a review.
Bandello, F; Borrelli, E; Corbelli, E; Giuffrè, C; Querques, G; Sacconi, R, 2019
)
1.07
"This fluocinolone acetonide implant has been designed for the treatment of non-infectious uveitis affecting the posterior segment of the eye and other eye disorders, which benefit from local anti-inflammatory therapy."( Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant.
, 2005
)
2.23

Treatment

Fluocinolone acetonide insert-treated eyes had significantly reduced uveitis recurrence rates throughout the study duration, significantly increased recurrence-free durations, fewer recurrence episodes among those with recurrences, less adjunctive therapy, and an acceptable side-effect profile.

ExcerptReferenceRelevance
"Fluocinolone acetonide insert-treated eyes had significantly reduced uveitis recurrence rates throughout the study duration, significantly increased recurrence-free durations, fewer recurrence episodes among those with recurrences, less adjunctive therapy, and an acceptable side-effect profile compared with sham-treated eyes."( Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
Jaffe, GJ; Pavesio, CE, 2020
)
2.38
"Fluocinolone acetonide treatment had no effect on this parameter."( The effect of topical drugs on mouse ear epidermal transglutaminase activity.
Ballaron, S; De Young, L, 1982
)
0.99

Toxicity

ExcerptReferenceRelevance
"Fourteen patients suffering from rosacea treated by prolonged topical applications of fluorinated steroids showed adverse effects."( Adverse effect of topical fluorinated corticosteroids in rosacea.
Sneddon, I, 1969
)
0.25
"The present review summarized the state of our knowledge on glucocorticosteroids, their mechanisms of action, pharmacological effects, pharmacokinetics and adverse effects."( [Glucocorticosteroids: mechanism of action, pharmacological effects, pharmacokinetics and adverse effects].
Tarchalska-Kryńska, B, 1994
)
0.29
" The treatment groups also did not differ significantly in the number of adverse events or in the incidence of oropharyngeal Candida infection."( Comparison of efficacy and safety between flunisolide/AeroChamber and budesonide/turbuhaler in patients with moderate asthma. AER-MD-04 Study Group.
Knight, A; Newhouse, M; Newman, K; Wang, S, 2000
)
0.31
" An added built-in spacer has reduced oropharyngeal deposition that may result in fewer adverse events and make it easier to use."( One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma.
Anolik, R; Gillman, SA; Newman, K; Schenkel, E, 2002
)
0.31
" The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation."( Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
Baumann, L; Jarratt, MM; Jones, T; Lowe, N; Martin, D; Menter, A; Pariser, D; Ramirez, N; Rich, P; Shavin, J; Taylor, SC; Torok, H; Tschen, E; Weiss, J; Wieder, JJ, 2003
)
0.32
" In addition, one of the photoproducts (the 17-hydroperoxy derivative) is highly toxic in the dark."( Photochemistry and phototoxicity of fluocinolone 16,17-acetonide.
Albini, A; Caffieri, S; Dalzoppo, D; Fasani, E; Miolo, G; Ricci, A,
)
0.13
" only 3 patients (1%) withdrew from the study due to treatment-related adverse events (AEs)."( Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma.
Jones, T; Rich, P; Smith, S; Torok, HM; Tschen, E, 2005
)
0.61
"5%) discontinued the study due to treatment-related adverse events (AEs)."( A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
Baumann, L; Jarret, M; Jones, T; Lowe, N; Martin, D; Menter, A; Pariser, D; Rich, P; Taylor, S; Torok, H; Tschen, E; Weiss, J; Wieder, J,
)
0.13
" We found sufficient evidence to support the suspicion that hypertrichosis might be a true adverse effect of ICS."( Hypertrichosis as a side effect of inhaled steroids in children.
de Jong-Van den Berg, LT; de Langen-Wouterse, JJ; de Vries, TW; Duiverman, EJ, 2007
)
0.34
" Safety was assessed through the reporting of adverse events."( A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan, R; Chang, SE; Kerrouche, N; Lee, ES; Lee, MH; Legarda-Montinola, F; Leow, YH; Park, KC; Shek, S; Tay, YK; Thomas, G; Tsai, RY; Tsai, TH; Verallo-Rowell, V, 2008
)
0.57
" More patients had related adverse events on TC (63/129, 48."( A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan, R; Chang, SE; Kerrouche, N; Lee, ES; Lee, MH; Legarda-Montinola, F; Leow, YH; Park, KC; Shek, S; Tay, YK; Thomas, G; Tsai, RY; Tsai, TH; Verallo-Rowell, V, 2008
)
0.57
"01% in a blend of refined peanut and mineral oils has been established as effective and safe treatment for atopic dermatitis in patients 2 years and older, including those with peanut sensitivity, for several years."( Fluocinolone acetonide 0.01% in peanut oil: safety and efficacy data in the treatment of childhood atopic dermatitis in infants as young as 3 months of age.
Alvarez-Connelly, E; Dohil, MA; Eichenfield, LF,
)
1.57
" Adverse events included increased intraocular pressure (54."( Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.
Aziz, K; Bajwa, A; Foster, CS, 2014
)
0.71
"1%) reported adverse effects."( Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Dang, Y; Gong, Z; Lai, W; Li, L; Liu, L; Wang, X; Yang, Q; Zhao, G; Zheng, M; Zou, Y, 2015
)
0.73
"7%) of the patients receiving fluocinolone presented with adverse events related to study medication."( Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial.
Ansley, J; Butehorn, HF; Byers, J; Douglis, F; Esterhuizen, K; Hernández, FJ; Hussain, I; Ismail, K; Lanier, B; Lansford, B; Pumarola, F; Spektor, Z, 2017
)
0.46
"The combination of ciprofloxacin plus fluocinolone is more effective than treatment with ciprofloxacin or fluocinolone alone for AOMT, and it is safe and well tolerated in children."( Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial.
Ansley, J; Butehorn, HF; Byers, J; Douglis, F; Esterhuizen, K; Hernández, FJ; Hussain, I; Ismail, K; Lanier, B; Lansford, B; Pumarola, F; Spektor, Z, 2017
)
0.46
"This prospective and pilot study suggests that ILUVIEN® is safe and may be considered effective for chronic DME patients insufficiently responsive to other available therapies as it showed a rapid and sustained improvement of macular edema obtained after treatment with ILUVIEN®."( A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND).
Alves, D; Amaro, M; Cunha-Vaz, J; Figueira, J; Henriques, J; Rosas, V, 2017
)
0.46
" Incidence and severity of adverse events was similar between the fluocinolone and placebo groups."( Efficacy and safety of fluocinolone acetonide 0.025% otic solution in patients with otic eczema: a randomized, double-blind, placebo-controlled clinical trial.
Asensio, C; Gavilanes, J; Langdon, C; Lorente, J; Martínez, Á; Montojo, J; Montoro, V; Prades, E; Rodríguez, FJ; Sarría, P, 2018
)
0.79
"The ILUVIEN implant was effective and safe in the treatment of multi-ethnic patients with diabetic macular oedema refractory to conventional therapies, improving the vision and macular anatomy, without significant adverse events up to 36 months post-treatment."( The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
Arruti, N; Panos, GD; Patra, S, 2021
)
0.89
" Other IOP-related signals and their relationship to previous corticosteroid exposure, best-corrected visual acuity, central subfield thickness (CST), ocular adverse events and frequency of other treatments were also measured."( Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
Eichenbaum, D; Holekamp, NM; Kaba, S; Kiernan, DF; Mansour, SE; Roth, DB; Werts, E, 2021
)
0.87
" Fifteen adverse events related to study medications were registered, all of which were mild or moderate."( Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Aazami, H; Acosta, AM; Ansley, JF; Chu, L; De Valle, O; Dennis, P; Ehmer, D; Hedrick, JA, 2022
)
0.99
" Secondary outcome measures were onset or progression of glaucoma and investigator-reported adverse events."( Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months.
Adán, A; Coelho-Borges, AI; Hernanz, I; Llorenç, V; Moll-Udina, A; Pazos, M; Pelegrín, L; Sainz-de-la-Maza, M, 2023
)
1.28
"The FAc implant is safe and effective at treating NIU over 12 months in a real-world setting in Spain."( Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months.
Adán, A; Coelho-Borges, AI; Hernanz, I; Llorenç, V; Moll-Udina, A; Pazos, M; Pelegrín, L; Sainz-de-la-Maza, M, 2023
)
1.28

Pharmacokinetics

ExcerptReferenceRelevance
" Minor fluctuations in the plasma profile after patch application were observed, even if no significant difference was found between the two formulations with regard to peak plasma concentration, time to reach peak levels, area under the concentration curve and half-life."( Pharmacokinetics of fluocinolone acetonide in patch versus cream formulations.
Benvenuti, C; Botta, V; Broccali, G; Broggini, M, 1991
)
0.6
" In a study of 12 healthy men, pharmacokinetic parameters were determined after single doses of 1000 microg CFC flunisolide delivered without a spacer, 340 microg HFA flunisolide delivered through a spacer, and 516 microg HFA flunisolide delivered without a spacer."( Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide.
Abramowitz, W; Nolting, A; Sista, S, 2002
)
0.31
" The values of these pharmacokinetic parameters were significantly higher in the flunisolide CFC group than in the 340 microg bid flunisolide HFA group on days 1 and 14."( Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers.
Abramowitz, W; Nolting, A; Sista, S, 2001
)
0.31
" In this paper, we review and unite pharmacokinetic data, case reports and current research regarding this drug-drug interaction in order to suggest options for the clinical management of HIV-positive patients requiring treatment with protease inhibitors and inhaled or intranasal corticosteroids."( Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management.
Nguyen, DP; Phengrasamy, T; Saberi, P, 2013
)
0.39
"Available corticosteroids for diabetic macular edema exhibit different pharmacokinetic profiles that impact efficacy and adverse events and should be taken into account when developing individualized treatment plans."( INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS.
Bailey, C; Loewenstein, A; Massin, P; Yang, Y, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
" Seventeen adults whose asthma symptoms had been stable for at least three months on 100-400 microgram/day of beclomethasone dipropionate aerosol received flunisolide intranasal solution (200 microgram/day) combined with its intrabronchial form (1 mg/day) or with beclomethasone dipropionate bronchial aerosol (400 microgram/day)."( Flunisolide intranasal solution combined with intrabronchial steroids in adults with both bronchial asthma and perennial rhinitis.
Gale, AE; Harding, P; Solomon, E, 1981
)
0.26
" Single session IPL combined with stable fixed-dose triple combination treatment is a safe and effective treatment for refractory mixed and dermal melasma."( Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma.
Figueiredo Souza, L; Trancoso Souza, S,
)
0.13
"We identified uveitic glaucoma patients with AGV surgery alone and AGV surgery combined with fluocinolone implant from the Massachusetts Eye and Ear Ocular Inflammation Database."( A retrospective study on the outcomes of Ahmed valve versus Ahmed valve combined with fluocinolone implant in uveitic glaucoma.
Cho, H; Davoudi, S; Guo, R; Lobo, AM; Papaliodis, GN; Sevgi, DD; Shen, LQ; Sobrin, L; Talcott, KE; Turalba, A, 2017
)
0.46
"This study introduces fluocinolone acetonide (FA) microemulsion in combination with ablative fractional lasering as a new effective treatment for scalp psoriasis."( Fluocinolone Acetonide Microemulsion in Combination with a Fractional Laser for the Treatment of Scalp Psoriasis.
Muangsiri, W; Vejjabhinanta, V; Werawatganone, P, 2022
)
2.48

Bioavailability

ExcerptReferenceRelevance
" This indicates that in vitro data can be useful in predicting oral bioavailability of GCS."( Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver.
Andersson, P; Lihné, M; Ryrfeldt, A; Thalén, A, 1987
)
0.27
" Flunisolide has high bioavailability when administered to normal subjects (50% of an intranasal dose reaches the systemic circulation) with minimal systemic effects."( A comparison of intranasal and oral flunisolide in the therapy of allergic rhinitis. Evidence for a topical effect.
Bush, R; Busse, W; Chaplin, M; Koshiver, J; Kwaselow, A; McLean, J; Metzger, W; Reed, C; Richerson, H; Shulan, D, 1985
)
0.27
"To examine the absolute bioavailability of flunisolide given orally via metered dose inhaler, and metered dose inhaler with a commercially available spacer device as well as to determine the fraction of drug deposited in the lungs following inhalation."( Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration.
Abramowitz, W; Choudhury, S; Dickens, GR; Foster, T; John, W; Matheny, CJ; Sista, SM; Wermeling, DP, 2000
)
0.31
"Flunisolide is a corticosteroid with low oral bioavailability (6."( Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration.
Abramowitz, W; Choudhury, S; Dickens, GR; Foster, T; John, W; Matheny, CJ; Sista, SM; Wermeling, DP, 2000
)
0.31
" Systemic bioavailability of INSs, by way of nasal and intestinal absorption, can be substantial; but current INSs vary significantly in their degree of first-pass hepatic inactivation and clearance from the body of the swallowed drug."( Systemic effects of intranasal steroids: an endocrinologist's perspective.
Allen, DB, 2000
)
0.31
"The goal of this study was to establish a reliable method to evaluate systemic bioavailability and to determine equisystemic effects (microgram dose producing equal systemic cortisol suppression) of inhaled corticosteroids (ICS)."( Systemic effect comparisons of six inhaled corticosteroid preparations.
Boushey, HA; Cherniack, RM; Chinchilli, VM; Craig, TJ; Dolovich, M; Drazen, JM; Fagan, JK; Fahy, JV; Fish, JE; Ford, JG; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, CA; Szefler, SJ, 2002
)
0.31
" Its oral bioavailability is poor (6."( A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience.
Fiocchi, A; Kantar, A; Mroueh, S,
)
0.13

Dosage Studied

ExcerptRelevanceReference
"025% solution of flunisolide, the total daily dosage was 200 microgram."( Flunisolide--a new intranasal steroid for the treatment of allergic rhinitis.
Chatterjee, SS; Engler, C; Sahay, JN, 1979
)
0.26
" Many reduced the dosage from three times to twice or once daily without losing benefit."( Flunisolide nasal spray for perennial rhinitis in children.
Sarsfield, JK; Thomson, GE, 1979
)
0.26
" Conventional doses may not be sufficient to provide control in many patients, and dosing should be tailored to the individual."( Inhaled steroids in asthma.
Dworski, R; Sheller, J, 1992
)
0.28
" During T2, half (group A) continued this dosing regimen, while the other half (group B) switched to two inhalations qid."( A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide.
Eliasson, O; Mann, M; Patel, K; ZuWallack, RL, 1992
)
0.28
" The synergistic effects of oral CsA and topical FA is significant, and thus allows for the use of a subtherapeutic dosage of each compound and provides a potentially safe means for prolonging skin allograft survival."( The synergistic effect of low-dose cyclosporine and fluocinolone acetonide on the survival of rat allogeneic skin grafts.
Alexander, JW; Babcock, GF; Schroeder, T; Zhao, XF, 1988
)
0.53
" The study design was open because of the different dosage schedules for the two preparations."( Comparative trial of flunisolide and beclomethasone dipropionate nasal sprays in patients with seasonal allergic rhinitis.
Ojala, K; Palva, A; Sipilä, P; Sorri, M, 1983
)
0.27
" Dose-response curves gave the following rank order of potency: fluocinolone greater than dexamethasone greater than hydrocortisone."( Glucocorticoid inhibition of zymosan-induced arachidonic acid release by rat alveolar macrophages.
Bathon, J; Flores, R; Hirata, F; Newcombe, DS; Peters-Golden, M, 1984
)
0.27
" The dosage of flunisolide was two actuations (25 micrograms/actuation) into each nostril twice a day (total 200 micrograms)."( A comparative trial of flunisolide and beclomethasone dipropionate in the treatment of perennial allergic rhinitis.
Chatterjee, SS; Engler, C; Sahay, JN, 1980
)
0.26
" During such outbreaks the use of flunisolide not only delayed the need for more prednisone but also reduced the dosage needed."( Episodic asthma as a bronchial provocation test.
Izu, AE; Leech, SH; Rolston, BS, 1980
)
0.26
" Eighteen of these patients were followed in an open study and evaluated at intervals for side effects and dosage of spray used."( Short-term efficacy trial and twenty-four-month follow-up of flunisolide nasal spray in the treatment of perennial rhinitis.
Busse, W; Clayton, DE; Cohen, M; Geller, M; Kooistra, JB; Ouellette, J; Reed, CE, 1981
)
0.26
"With use of partial suppression of immediate response to inhaled allergen and 24-hour urinary free cortisol output, three-point dose-response curves were constructed for beclomethasone dipropionate (50 micrograms/puff), triamcinolone acetonide (100 micrograms/puff), and flunisolide (250 micrograms/puff)."( A bioassay for topical and systemic effect of three inhaled corticosteroids.
Ahrens, R; Grandgeorge, S; McCubbin, MM; Milavetz, G; Sargent, C; Vaughan, LM; Weinberger, M, 1995
)
0.29
" Dose-response relationships were shown for each inhaled corticosteroid for both topical and systemic effect."( A bioassay for topical and systemic effect of three inhaled corticosteroids.
Ahrens, R; Grandgeorge, S; McCubbin, MM; Milavetz, G; Sargent, C; Vaughan, LM; Weinberger, M, 1995
)
0.29
"The purpose of this study was to evaluate the feasibility of switching to once-daily (qd) administration of flunisolide in patients with asthma that was controlled by twice-daily (bid) dosing of this inhaled steroid."( The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control.
Bodenheimer, S; Bronsky, EA; Chervinsky, P; Cohen, L; Corren, J; Goldsobel, AB; Gong, H; Kaliner, MA; Lotner, GZ; Rachelefsky, GS; Rosen, JP; White, MV; ZuWallack, RL, 1997
)
0.3
" Depending on the intensity of allergen exposure, complaints now occur in February/March only, requiring updating of the therapy in respect of dosage and number of drugs used."( [Two out-of-the-ordinary (?) case reports an asthmatic disease].
Hausen, T, 2000
)
0.31
" A review of available information indicates that (1) sensitive tests can measure the effects of INSs on biologic feedback systems, but they do not accurately predict clinically relevant adverse effects; (2) the primary factors that influence the relationship between therapeutic and adverse systemic effects of INSs are dosing frequency and efficiency of hepatic inactivation of swallowed drug; (3) INS treatment in recommended doses does not cause clinically significant hypothalamic-pituitary-adrenal axis suppression; (4) growth suppression can occur with twice-daily administration of certain INSs but does not appear to occur with once-daily dosing or with agents with more complete first-pass hepatic inactivation; (5) harmful effects of INSs on bone metabolism have not yet been adequately studied but would not be expected with the use of an INS dose and dosing frequency that do not suppress basal hypothalamic-pituitary-adrenal axis function or growth; and (6) these conclusions apply to INS treatment alone and in recommended doses-the risk of adverse effects in individual patients who are treated with INSs is increased by excessive dosing or concomitant inhaled corticosteroid or other topical corticosteroid therapy."( Systemic effects of intranasal steroids: an endocrinologist's perspective.
Allen, DB, 2000
)
0.31
" The algorithm was designed to calculate CCS based on 5 input parameters: name of drug, dose, dosing interval, time(s) of dosing, and type of inhaler device."( An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy.
Derendorf, H; Hochhaus, G; Krishnaswami, S, 2000
)
0.31
" Dosing was continued for 13."( Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers.
Abramowitz, W; Nolting, A; Sista, S, 2001
)
0.31
" For the six ICS and matching placebos (beclomethasone-chlorofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC), only the placebo group and fluticasone DPI did not demonstrate a significant dose-response effect."( Systemic effect comparisons of six inhaled corticosteroid preparations.
Boushey, HA; Cherniack, RM; Chinchilli, VM; Craig, TJ; Dolovich, M; Drazen, JM; Fagan, JK; Fahy, JV; Fish, JE; Ford, JG; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, CA; Szefler, SJ, 2002
)
0.31
" The objective of this study was to compare the year-long safety of flunisolide HFA (daily dosage 340 microg) with that of CFC beclomethasone dipropionate (BDP) (daily dosage 336 microg) and cromolyn sodium (daily dosage 6,400 microg) in children 4-11 years old with mild-to-moderate asthma."( One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma.
Anolik, R; Gillman, SA; Newman, K; Schenkel, E, 2002
)
0.31
" Flunisolide HFA, at one-third the dosage (170 and 340 microg twice daily), had similar efficacy to flunisolide CFC (500 and 1000 microg twice daily) and significantly greater efficacy than placebo in a randomized, double-blind, placebo-controlled, 12-week study in patients with mild to moderate asthma."( Flunisolide HFA.
Goa, KL; Waugh, J, 2002
)
0.31
" A single dose-response study has been performed in adults and in children comparing multiple doses of flunisolide HFA and flunisolide CFC."( Flunisolide HFA for the treatment of asthma: an old friend reformulated.
Colice, G; Shafazand, S, 2004
)
0.32
" There was a reduction in systemic and local therapy use in the device-implanted eyes; of the patients who remained on systemic medication after implantation, dosage was reduced in 68%."( Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Ashton, P; Branchaud, B; Butuner, Z; Jaffe, GJ; McCallum, RM; Skalak, C, 2005
)
0.58
"In all, 25 patients completing the study per protocol were treated daily for 24 weeks (cohort A); 6 patients were treated daily for 12 weeks followed by 12 weeks of maintenance therapy (cohort B); and 21 patients were treated daily for 12 weeks, relapsed during the maintenance phase, and returned to daily dosing (cohort C)."( Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.
Bhawan, J; Colón, LE; Gottschalk, RW; Grimes, PE; Guevara, IL; Johnson, LA; Pandya, AG, 2010
)
0.36
"Fluocinolone acetonide intravitreal implant reduced uveitis recurrence rate and the dosage of systemic corticosteroid and immunosuppressant requirement in patients with Vogt-Koyanagi-Harada."( FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety.
Cho, BJ; Do, DV; Goldstein, DA; Heo, JW; Nguyen, QD; Sepah, YJ, 2016
)
3.32
" Of the 6 participants who continued receiving systemic medication after implantation, the dosage was reduced in 4 participants."( Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Ashton, P; Jaffe, GJ; Keenan, RT; Lin, P; Skalak, C; Stinnett, SS, 2016
)
0.82
" From the results, we conclude that new formulations will greatly reduce drug dosage and frequency of administration for long term treatment of inflammation in posterior part of the eye."( Enhancing the efficacy of fluocinolone acetonide by encapsulating with PLGA nanoparticles and conjugating with linear PEG polymer.
Ahmad, M; Guru, BR; Pinto, J, 2019
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anti-inflammatory drugA substance that reduces or suppresses inflammation.
antipruritic drugA drug, usually applied topically, that relieves pruritus (itching).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (9)

ClassDescription
11beta-hydroxy steroidAny 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
21-hydroxy steroid
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
cyclic ketalA ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
glucocorticoidGlucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
fluorinated steroidA steroid which is substituted with one or more fluorine atoms in any position.
3-oxo-Delta(1),Delta(4)-steroidA 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
organic heteropentacyclic compound
primary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
SMAD family member 2Homo sapiens (human)Potency24.54120.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency24.54120.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency0.01640.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency67.89390.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.11690.000221.22318,912.5098AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743054; AID743063
Smad3Homo sapiens (human)Potency0.10000.00527.809829.0929AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.00130.00137.762544.6684AID914; AID915
progesterone receptorHomo sapiens (human)Potency0.00140.000417.946075.1148AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency9.79310.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.00450.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency57.76480.003041.611522,387.1992AID1159552; AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency35.96710.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency16.19940.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.61390.000229.305416,493.5996AID743069; AID743080; AID743091
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency36.66360.023723.228263.5986AID743222; AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.00450.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.60320.001628.015177.1139AID1259385
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency11.22020.10009.191631.6228AID1346983
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.16230.039816.784239.8107AID1454
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.23870.15855.287912.5893AID540303
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency13.68540.002319.595674.0614AID651631
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.00860.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency0.00860.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)0.00310.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki0.00140.00010.38637.0010AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.00310.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.00140.00070.76537.0010AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki0.00140.00070.78467.0010AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.00310.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.00140.00070.78467.0010AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00310.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.00140.00070.78467.0010AID625263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (165)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (101)

Assay IDTitleYearJournalArticle
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID188016Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1071716Antimicrobial activity against Aspergillus viridinutans at 250 ug/disc after 5 to 7 days by well diffusion method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409955Inhibition of mouse liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID128359Systemic corticosteroid activity after topical application relative to fluocinolone acetonide in mice.1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID91225Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay; Potent1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID128696Topical anti-inflammatory activity relative to fluocinolone acetonide in mice.1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID88904Tested for human vasoconstrictor activity relative to fluocinolone acetonide (100)1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1133643Thymolytic activity in rat assessed as inhibition of thymus weight administered topically measured per pellet1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and topical antiinflammatory properties of 17,21-bis(acetyloxy)-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione and related 2-halogenated compounds.
AID1133642Antiinflammatory activity in rat assessed as inhibition of cotton pellet-induced granuloma weight administered topically measured per pellet1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and topical antiinflammatory properties of 17,21-bis(acetyloxy)-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione and related 2-halogenated compounds.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID171622Topical anti-inflammatory activity relative to fluocinolone acetonide in rats.1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID168364Systemic corticosteroid activity after topical application relative to fluocinolone acetonide in rats.1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates.
AID221791Potency relative to fluocinolone 16,17-acetonide(Experimental vasoconstictor activity) in human1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1071717Antimicrobial activity against Aspergillus niger at 250 ug/disc after 5 to 7 days by well diffusion method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,390)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990784 (56.40)18.7374
1990's125 (8.99)18.2507
2000's143 (10.29)29.6817
2010's232 (16.69)24.3611
2020's106 (7.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.51 (24.57)
Research Supply Index7.54 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index142.75 (26.88)
Search Engine Supply Index2.13 (0.95)

This Compound (74.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials389 (26.07%)5.53%
Reviews104 (6.97%)6.00%
Case Studies110 (7.37%)4.05%
Observational13 (0.87%)0.25%
Other876 (58.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (41)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Observational Bilateral Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant for at Least One Year [NCT01060787]98 participants (Actual)Observational2016-02-04Completed
A Controlled, Multi-Center Study of the Utilization and Safety of the MkII Inserter and the Safety of the FAI Insert in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye. [NCT02748512]Phase 326 participants (Actual)Interventional2016-02-23Completed
A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg [NCT02424019]Phase 4153 participants (Actual)Interventional2015-05-06Completed
A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy ( [NCT02359526]Phase 412 participants (Actual)Interventional2014-10-31Completed
Phase 4 Study of YUTIQ® (Fluocinolone Acetonide Intravitreal Implant) 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (Intraocular Inflammation Study) [NCT05322070]Phase 4125 participants (Anticipated)Interventional2022-06-06Recruiting
Multicenter Uveitis Steroid Treatment (MUST) Trial [NCT00132691]Phase 4255 participants (Actual)Interventional2005-09-30Completed
A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) [NCT04469595]Phase 4300 participants (Anticipated)Interventional2020-08-31Active, not recruiting
An Open Label Pharmacokinetic and Efficacy Study of 0.5 μg/Day and 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts in Subjects With Diabetic Macular Edema [NCT00490815]Phase 337 participants (Actual)Interventional2007-08-31Completed
Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment [NCT00543296]Phase 421 participants (Actual)Interventional2004-03-31Completed
Split-Face, Randomized, Open-Label Study of Sequential Treatment With Tri-Luma® Cream With Intense Pulsed Light (IPL) vs. a Mild Inactive Control Cream With Intense Pulsed Light (IPL) in Subjects With Melasma [NCT00669071]Phase 456 participants (Actual)Interventional2008-01-31Terminated(stopped due to Enrollment closed)
[NCT01304706]Phase 3120 participants (Actual)Interventional2011-04-30Completed
Comparison Of The Efficacy Of Combination Of TAM Formula Versus Kligman Formula For Melasma At Tertiary Care Hospital,Karachi. [NCT06013540]Phase 2122 participants (Actual)Interventional2022-08-01Active, not recruiting
A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy [NCT05844982]Phase 3600 participants (Anticipated)Interventional2023-11-21Recruiting
A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/Day and ASI-001B 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Ed [NCT00344968]Phase 3956 participants (Actual)Interventional2007-09-30Completed
Combined Anti-VEGF Intravitreal Injections With Sustained Steroid Implantation for the Treatment of Diabetic Macular Oedema [NCT03784443]Phase 2/Phase 30 participants (Actual)Interventional2019-09-01Withdrawn(stopped due to Funder withdrawn funding.)
A Randomized, Double-Masked, Fellow-Eye Comparison Of The Safety And Efficacy Of 0.2 And 0.5 µg/Day Fluocinolone Acetonide Intravitreal Insert To Sham Injection In Subjects With Bilateral Geographic Atrophy Due To AMD [NCT00695318]Phase 217 participants (Actual)Interventional2008-12-31Terminated
A Randomized, Prospective Study of Sustained-Release Fluocinolone Acetonide Implant for Choroidal Neovascularization Associated With Age-Related Macular Degeneration [NCT00008515]Phase 116 participants Interventional2001-01-31Completed
A Randomized, Controlled Pilot Study to Evaluate the Safety and Efficacy of Intravitreal Fluocinolone Acetonide (0.5mg and 2mg) Implants in Patients With Clinically Significant Diabetic Macular Edema [NCT00576459]Phase 240 participants (Actual)Interventional2003-03-31Completed
Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients With Severe Uveitis [NCT00570830]21 participants (Actual)Interventional2006-09-30Completed
A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien™ (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Edema Secondary to Retinal Vein Occlusion [NCT00770770]Phase 220 participants (Actual)Interventional2009-05-31Terminated
A Pilot Study of a Sustained-Release Fluocinolone Implant for Treatment of Retinal Vein Occlusion [NCT00636493]Early Phase 130 participants (Actual)Interventional2002-10-31Completed
A Pilot Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion [NCT00952614]29 participants (Actual)Interventional2002-10-31Completed
Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study [NCT02902744]Phase 40 participants (Actual)Interventional2017-03-01Withdrawn(stopped due to The study was withdrawn due to difficult recruitment of patients for the study; No participants were enrolled in the study.)
A Phase III, Multicenter, Randomized, Evaluator-blinded, Parallel-Group, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Ciprofloxacin 0.3% Plus Fluocinolone Acetonide 0.025% Otic Solution in the Treatment of Acute Otitis Externa ( [NCT04636957]Phase 3600 participants (Anticipated)Interventional2020-11-30Not yet recruiting
A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye [NCT00456482]Phase 2/Phase 3239 participants (Actual)Interventional2002-05-31Terminated(stopped due to SARS epidemic in Asia and Canada)
A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye [NCT00407082]Phase 2/Phase 3278 participants (Actual)Interventional2000-12-31Completed
A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye [NCT00468871]Phase 2/Phase 3140 participants (Actual)Interventional2002-04-30Completed
A Multicenter, Randomized, Masked, Controlled Study to Evaluate Retisert, and Intravitreal Fluocinolone Acetonide Implant, in the Treatment of Patients With Diabetic Macular Edema [NCT00502541]Phase 2/Phase 3196 participants (Actual)Interventional2001-09-30Completed
[NCT00032396]Phase 20 participants Interventional2001-11-30Active, not recruiting
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant [NCT03145025]3 participants (Actual)Observational2017-07-14Completed
A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur™ in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis™ [NCT00605423]Phase 26 participants (Actual)Interventional2008-01-31Completed
Prospective Imaging of the intrAvitreal fluocinoloNe Acetonide Implant Using Fluorescein Angiography and opTical coHerencE tomogRaphy in Uveitis Patients. (PANTHER) [NCT04340505]30 participants (Anticipated)Observational2019-08-08Recruiting
The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus [NCT01743690]25 participants (Actual)Interventional2012-03-31Completed
Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis [NCT01781936]Phase 117 participants (Actual)Interventional2012-06-30Completed
An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma [NCT00469183]Phase 470 participants (Actual)Interventional2006-05-31Completed
Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema [NCT04910503]Phase 4106 participants (Anticipated)Interventional2021-10-29Recruiting
A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye [NCT02746991]Phase 3153 participants (Actual)Interventional2015-06-02Completed
Steroids for Early Treatment of Radiation Retinopathy [NCT03238157]Phase 2/Phase 30 participants (Actual)Interventional2022-02-01Withdrawn(stopped due to Lack of funding)
[NCT02472366]Phase 416 participants (Actual)Interventional2014-01-31Completed
Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma [NCT00472966]Phase 420 participants (Actual)Interventional2006-11-30Completed
Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates [NCT03590587]30 participants (Anticipated)Observational2017-01-13Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00132691 (17) [back to overview]Change in SF-36 Physical Component Score From Baseline to 24 Months
NCT00132691 (17) [back to overview]Cataract - Incident Cataract
NCT00132691 (17) [back to overview]Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis
NCT00132691 (17) [back to overview]Change in Self-reported Vision-related Function as Measured by the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ 25) Vision Targeted Composite Score From Baseline to 24 Months
NCT00132691 (17) [back to overview]Change in SF-36 Mental Component Score From Baseline to 24 Months
NCT00132691 (17) [back to overview]Intraocular Pressure - Incident IOP Greater Than or Equal to 24 mm Hg
NCT00132691 (17) [back to overview]Diabetes Mellitus
NCT00132691 (17) [back to overview]Glaucoma - Incident
NCT00132691 (17) [back to overview]Hyperlipidemia - Incident
NCT00132691 (17) [back to overview]Hypertension Diagnosis Requiring Treatment
NCT00132691 (17) [back to overview]Intraocular Pressure - Incident IOP Elevation >= 10 mmHg Above Baseline
NCT00132691 (17) [back to overview]Intraocular Pressure - Incident IOP Greater Than or Equal to 30 mm Hg
NCT00132691 (17) [back to overview]Intraocular Pressure - IOP-lowering Surgery
NCT00132691 (17) [back to overview]Intraocular Pressure (IOP) - Incident Use of IOP-lowering Medical Therapy (Percentage of Eyes With Uveitis That Were Not Being Treated With IOP-lowering Medical Therapy at Baseline and Underwent IOP Lowering Therapy During the 24 Month Follow-up.
NCT00132691 (17) [back to overview]Macular Edema
NCT00132691 (17) [back to overview]Mortality
NCT00132691 (17) [back to overview]Uveitis Activity
NCT00344968 (2) [back to overview]Visual Acuity
NCT00344968 (2) [back to overview]Retinal Thickness
NCT00490815 (2) [back to overview]Levels of Fluocinolone Acetonide in Plasma and Aqueous Humor
NCT00490815 (2) [back to overview]Retinal Thickness
NCT00543296 (4) [back to overview]Number of Eyes With Increased Intraocular Pressure
NCT00543296 (4) [back to overview]Number of Eyes With Inflammation Recurrence
NCT00543296 (4) [back to overview]Percentage of Eyes With Improvement in Visual Acuity
NCT00543296 (4) [back to overview]Number of Participant's Eye Requiring Adjunctive Therapy
NCT00605423 (3) [back to overview]Change in IOP From Baseline
NCT00605423 (3) [back to overview]Mean Change From Baseline in Visual Acuity
NCT00605423 (3) [back to overview]Number of Patients Developing Cataracts
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Subject's Evaluation of Improvement
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Investigator's Evaluation of Improvement
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Subject's Evaluation of Improvement
NCT00669071 (8) [back to overview]Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 10 as Evaluated Using the Investigator's Global Assessment (IGA) of Melasma
NCT00669071 (8) [back to overview]Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 6 Using the Investigator's Global Assessment (IGA) of Melasma With Clear/Almost Clear Being Success and All Others Being Failure
NCT00669071 (8) [back to overview]Number of Participants With Tolerability Assessments Resulting in Adverse Events
NCT00669071 (8) [back to overview]Degree of Pigmentation (Melanin) Using a Mexameter at Weeks 6 and 10
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Investigator's Evaluation of Improvement
NCT00695318 (1) [back to overview]Change From Baseline in Size of Geographic Atrophy
NCT00770770 (1) [back to overview]Visual Acuity
NCT00952614 (2) [back to overview]Improvement in Macular Edema on Optical Coherence Tomography and Color Photos
NCT00952614 (2) [back to overview]Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts
NCT01304706 (1) [back to overview]Number of Participants With Adverse Events
NCT02472366 (5) [back to overview]Changes in Macular Volume
NCT02472366 (5) [back to overview]Change in Best Corrected Visual Acuity From Baseline
NCT02472366 (5) [back to overview]Changes in Best Corrected Visual Acuity From Baseline
NCT02472366 (5) [back to overview]Changes in Central Subfield Thickness
NCT02472366 (5) [back to overview]Changes in Intraocular Pressure (IOP)
NCT02746991 (2) [back to overview]Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months
NCT02746991 (2) [back to overview]Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months
NCT02748512 (2) [back to overview]The Safety of the FAI Insert During 12 Months Following Treatment Reported as Percentages.
NCT02748512 (2) [back to overview]The Utilization of the Mk II Inserter From the Day of Treatment Through 7 Days Following Treatment.

Change in SF-36 Physical Component Score From Baseline to 24 Months

Self-reported health related QoL was measured with the SF 36 survey. The physical component score for the SF 36 is a summary measure of physical health primarily based on the physical functioning, role physical, bodily pain and general health domains of the survey. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. A 3 to 5 point difference is considered to be clinically meaningful. (NCT00132691)
Timeframe: 24 months

Interventionunits on a scale (Mean)
Flucinolone Acetonide Implant1.15
Systemic Therapy-1.8

[back to top]

Cataract - Incident Cataract

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant90.7
Systemic Therapy44.9

[back to top]

Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis

Best-corrected visual acuity was measured as the number of letters read from standard logarithmic visual acuity charts by study-certified examiners who were masked to treatment. Visual acuity was measured at all study visits. The primary outcome was eye-specific change in visual acuity from baseline to 2-year follow-up. Positive change values indicate improved vision while negative change values indicate vision has gotten worse. A change of 7.5 letters is considered clinically meaningful. (NCT00132691)
Timeframe: 24 months

Interventionletters (Mean)
Flucinolone Acetonide Implant6.0
Systemic Therapy3.2

[back to top] [back to top]

Change in SF-36 Mental Component Score From Baseline to 24 Months

Self-reported health related QoL was measured with the SF 36 survey. The mental component score for the SF 36 is a summary measure of mental health primarily based on the social functioning, role emotional, mental health and vitality domains. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. (NCT00132691)
Timeframe: 24 months

Interventionunits on a scale (Mean)
Flucinolone Acetonide Implant2.55
Systemic Therapy-1.1

[back to top]

Intraocular Pressure - Incident IOP Greater Than or Equal to 24 mm Hg

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant53.1
Systemic Therapy18.7

[back to top]

Diabetes Mellitus

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Flucinolone Acetonide Implant1.0
Systemic Therapy3.6

[back to top]

Glaucoma - Incident

Glaucoma was diagnosed by a glaucoma specialist through review of visual fields, clinical data, and fundus images. (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant16.5
Systemic Therapy4.0

[back to top]

Hyperlipidemia - Incident

LDL greater than or equal to 160 mg/mL (NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants at risk (Number)
Flucinolone Acetonide Implant9.8
Systemic Therapy11.0

[back to top]

Hypertension Diagnosis Requiring Treatment

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Flucinolone Acetonide Implant4.6
Systemic Therapy10.5

[back to top]

Intraocular Pressure - Incident IOP Elevation >= 10 mmHg Above Baseline

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant51.8
Systemic Therapy15.5

[back to top]

Intraocular Pressure - Incident IOP Greater Than or Equal to 30 mm Hg

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant32.8
Systemic Therapy6.3

[back to top]

Intraocular Pressure - IOP-lowering Surgery

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant26.2
Systemic Therapy3.7

[back to top]

Intraocular Pressure (IOP) - Incident Use of IOP-lowering Medical Therapy (Percentage of Eyes With Uveitis That Were Not Being Treated With IOP-lowering Medical Therapy at Baseline and Underwent IOP Lowering Therapy During the 24 Month Follow-up.

The percentage of subjects who used topical or systemic treatment for elevated IOP at any time during the 2 year follow-up and were not on IOP-lowering therapy at baseline is reported. (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant61.1
Systemic Therapy20.1

[back to top]

Macular Edema

center point macular thickness >= 240 micrometers assessed on OCT (Stratus OCT-3 [Carl Zeiss Meditec, Dublin, CA]) as graded by Central Reading Center (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis (Number)
Flucinolone Acetonide Implant22
Systemic Therapy30

[back to top]

Mortality

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Flucinolone Acetonide Implant1.6
Systemic Therapy0

[back to top]

Uveitis Activity

Uveitis activity was determined by clinician assessment at each study visit. The study ophthalmologist evaluated each eye as active, inactive/never had uveitis or cannot assess. (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis (Number)
Fluocinolone Acetonide Implant12
Systemic Therapy29

[back to top]

Visual Acuity

The percentage of subjects with an increase from baseline of 15 or more letters in best corrected visual acuity letter score as assessed by ETDRS eye chart (study eye). (NCT00344968)
Timeframe: 36 months

Interventionpercentage of subjects (Number)
Sham Comparator18.9
Fluocinolone Acetonide: 0.2 ug/Day Implant28.7
Fluocinolone Acetonide: 0.5 ug/Day Implant27.8

[back to top]

Retinal Thickness

Retinal images where sent to a reading center for analysis. Some images were not clear/distorted and could not be properly analyzed. This accounts for the discrepancy in the number of participants analyzed. (NCT00344968)
Timeframe: 36 months

Interventionmicrons (Mean)
Sham Comparator146.1
Fluocinolone Acetonide: 0.2 ug/Day Implant113.5
Fluocinolone Acetonide: 0.5 ug/Day Implant131.8

[back to top]

Levels of Fluocinolone Acetonide in Plasma and Aqueous Humor

This was a combined assessment of the levels of fluocinolone acetonide in the plasma and aqueous humor. The average values of the data collected is entered in Outcome Data. (NCT00490815)
Timeframe: over 36 months

Interventionpg/ml (Mean)
Fluocinolone Acetonide: 0.2 ug/Day Implant1.4905
Fluocinolone Acetonide: 0.5 ug/Day Implant0.7140

[back to top]

Retinal Thickness

(NCT00490815)
Timeframe: over 36 months

Interventionµg (Mean)
Fluocinolone Acetonide: 0.2 ug/Day Implant343.8
Fluocinolone Acetonide: 0.5 ug/Day Implant324.2

[back to top]

Number of Eyes With Increased Intraocular Pressure

(NCT00543296)
Timeframe: 52 weeks

Interventioneyes (Number)
0.59 mg Fluocinolone Acetonide Implant2

[back to top]

Number of Eyes With Inflammation Recurrence

Number of eyes with inflammation recurrence (NCT00543296)
Timeframe: 5 years

Interventioneye with inflammation (Number)
0.59 mg Fluocinolone Acetonide Implant1

[back to top]

Percentage of Eyes With Improvement in Visual Acuity

Visual acuity was improved by two or more lines from baseline. (NCT00543296)
Timeframe: baseline to 52 weeks

Interventionpercentage of eyes improved (Number)
0.59 mg Fluocinolone Acetonide Implant45

[back to top]

Number of Participant's Eye Requiring Adjunctive Therapy

Adjunctive Therapy needed to control inflammation in the implanted eye (NCT00543296)
Timeframe: 5 years

Interventionparticipant's eyes (Number)
Topical corticosteroidsSubTenon triamcinolone acetonide injectionPrednisoneIntravitreal triamcinolone acetonide injection
0.59 mg Fluocinolone Acetonide Implant12714

[back to top]

Change in IOP From Baseline

IOP stands for intra ocular pressure (NCT00605423)
Timeframe: 6 mos

InterventionmmHg (Mean)
Fluocinolone Acetonide: 0.2 ug/Day Implant1.30
Fluocinolone Acetonide: 0.5 ug/Day Implant2.65

[back to top]

Mean Change From Baseline in Visual Acuity

Visual acuity is measured using ETDRS charts at 4 meters. (NCT00605423)
Timeframe: 6 mos

InterventionETDRS letters (Mean)
Fluocinolone Acetonide: 0.2 ug/Day Implant1.8
Fluocinolone Acetonide: 0.5 ug/Day Implant1.0

[back to top]

Number of Patients Developing Cataracts

(NCT00605423)
Timeframe: 6 mos

Interventionparticipants (Number)
Fluocinolone Acetonide: 0.2 ug/Day Implant4
Fluocinolone Acetonide: 0.5 ug/Day Implant2

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Subject's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 10 using the Subject's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 10

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream36173
Intense Pulsed Light (IPL) / Tri-Luma® Cream4853

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Investigator's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 6 using the Investigator's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 6

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream40133
Intense Pulsed Light (IPL) / Tri-Luma® Cream4673

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Subject's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 6 using the Subject's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 6

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream33203
Intense Pulsed Light (IPL) / Tri-Luma® Cream4853

[back to top]

Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 10 as Evaluated Using the Investigator's Global Assessment (IGA) of Melasma

Number of participants who were a success or failure with regards to melasma severity at Week 10 as evaluated using the Investigator's Global Assessment (IGA) of melasma (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe) with Clear / Almost Clear being success and all others being failure (NCT00669071)
Timeframe: Baseline to week 10

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream13430
Intense Pulsed Light (IPL) / Tri-Luma® Cream32240

[back to top]

Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 6 Using the Investigator's Global Assessment (IGA) of Melasma With Clear/Almost Clear Being Success and All Others Being Failure

Number of participants who were a success or failure with regards to melasma severity at Week 6 as evaluated using the Investigator's Global Assessment (IGA) of melasma (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe) with Clear / Almost Clear being success and all others being failure (NCT00669071)
Timeframe: Baseline to week 6

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream8480
Intense Pulsed Light (IPL) / Tri-Luma® Cream23330

[back to top]

Number of Participants With Tolerability Assessments Resulting in Adverse Events

Number of participants with Tolerability assessments (erythema, scaling, dryness, stinging/burning, edema, telangiectasis, darkening or melasma spots) resulting in adverse events (NCT00669071)
Timeframe: Baseline to week 10

Interventionparticipants (Number)
Intense Pulsed Light (IPL) / Tri-Luma® Cream1
Intense Pulsed Light (IPL) / Inactive Control Cream0

[back to top]

Degree of Pigmentation (Melanin) Using a Mexameter at Weeks 6 and 10

Degree of pigmentation (melanin) using a Mexameter to record units on a scale at Weeks 6 and 10; units on a scale is a number that represents the presence or absence of melanin in the skin on a scale from 0 - 999 units with 0 units representing no melanin and 999 units representing the maximum amount of melanin. (NCT00669071)
Timeframe: Baseline to Week 6 and Baseline to Week 10

,
Interventionunits on a scale (Mean)
Week 6Week 10
Intense Pulsed Light (IPL) / Inactive Control Cream36.726.2
Intense Pulsed Light (IPL) / Tri-Luma® Cream27.515.1

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Investigator's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 10 using the Investigator's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 10

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream37163
Intense Pulsed Light (IPL) / Tri-Luma® Cream4493

[back to top]

Change From Baseline in Size of Geographic Atrophy

(NCT00695318)
Timeframe: 24 months

Interventionmm3/year (Mean)
A, 2, I Sham2.513
A, 2, I 0.2 µg/Day2.758
A, 2, II Sham2.599
A, 2, II 0.5 µg/Day2.562

[back to top]

Visual Acuity

To compare the 3 month best corrected visual acuity to baseline in subjects diagnosed with macular edema secondary to retinal vein occlusion. BCVA will be measured according to the standard procedure developed for ETDRS at 4 meters or 3 meters if the electronic (E)-ETDRS system is employed. (NCT00770770)
Timeframe: 3 months

,
InterventionLetters (Mean)
BaselineMonth 3 - Change from Baseline
Fluocinolone Acetonide 0.2 µg/Day47.07.0
Fluocinolone Acetonide 0.5 µg/Day53.59.2

[back to top]

Improvement in Macular Edema on Optical Coherence Tomography and Color Photos

Anatomic Change in reading of the size of the area of retinal thickening on color photographs and OCT. Total Macular Volume (TMV) in mm^3, is the calculated volume from the layers of the retina based off OCT imaging. (NCT00952614)
Timeframe: baseline (preoperatively) to 3 years postoperatively

Interventionimprovement in TMV/mm^3 (Mean)
Retisert for Retinal Vein Occlusion10.4

[back to top]

Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts

Outcome measure based on eyes at time points with 10-letter ETDRS score improvement (NCT00952614)
Timeframe: baseline (preoperatively) to 3 years postoperatively

Interventionletters read correctly (Mean)
Change in ETDRS @ 1 year after implantChange in ETDRS @ 2 years after implantChange in ETDRS @ 3 years after implant
Retisert for Retinal Vein Occlusion12.51413.5

[back to top]

Number of Participants With Adverse Events

This is a measurement of the number of subjects who experienced an adverse event and/or a serious adverse event during the trial. (NCT01304706)
Timeframe: 12 months

Interventionparticipants (Number)
Adverse EventSerious Adverse Event
Fluocinolone Acetonide10042

[back to top]

Changes in Macular Volume

(NCT02472366)
Timeframe: Change from Baseline to 12 months post ILUVIEN administration

Interventionmm^3 (Mean)
Laser-1.610
Laser and Anti-VEGF-1.137

[back to top]

Change in Best Corrected Visual Acuity From Baseline

A subgroup analysis was performed in which only pseudophakic subjects were included. Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye. (NCT02472366)
Timeframe: Change from Baseline to 12 months post ILUVIEN administration

InterventionBest Corrected VA Letter Score (Mean)
Laser5.6
Laser and Anti-VEGF9.4

[back to top]

Changes in Best Corrected Visual Acuity From Baseline

Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye. (NCT02472366)
Timeframe: Change from Baseline to 12 months post ILUVIEN administration

InterventionBest Corrected VA Letter Score (Mean)
Laser3.5
Laser and Anti-VEGF0.9

[back to top]

Changes in Central Subfield Thickness

(NCT02472366)
Timeframe: Change from Baseline to 12 months post ILUVIEN administration

Interventionmicrons (Mean)
Laser-362.2
Laser and Anti-VEGF-251.3

[back to top]

Changes in Intraocular Pressure (IOP)

(NCT02472366)
Timeframe: Change from Baseline to 12 months post ILUVIEN administration

InterventionmmHg (Mean)
Laser1.7
Laser and Anti-VEGF2.9

[back to top]

Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months

Proportion of Subjects with Recurrence of Uveitis in the Study Eye within 6 Months Including Reason for Imputed Recurrence (ITT Population) (NCT02746991)
Timeframe: 6 Months

InterventionParticipants (Count of Participants)
Sham Injection28
FAI Insert22

[back to top]

Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months

Proportion of Subjects with Recurrence of Uveitis in the Study Eye at 36 Months Including Reason for Imputed Recurrence (ITT Population) (NCT02746991)
Timeframe: 36 Months

InterventionParticipants (Count of Participants)
Sham Injection39
FAI Insert47

[back to top]

The Safety of the FAI Insert During 12 Months Following Treatment Reported as Percentages.

To assess the safety of the FAI insert during 12 months following treatment reported as percentages. (NCT02748512)
Timeframe: Month 12

,
InterventionEyes (Count of Units)
TEAESerious TEAETreatment-related TEAETreatment-related serious TEAETEAE leading to FAI insert removalTEAE leading to study discontinuationAE leading to death
Mk I Inserter7140100
Mk II Inserter121100000

[back to top]

The Utilization of the Mk II Inserter From the Day of Treatment Through 7 Days Following Treatment.

The primary utilization endpoint was defined as the proportion of intravitreal insertion procedures that were assessed by the investigator as satisfactory. A satisfactory procedure was defined as one receiving a score from the Investigator as either Very Easy, Easy, or Routine. (NCT02748512)
Timeframe: Day 7

,
InterventionEyes (Count of Units)
Very EasyEasyRoutineDifficultVery Difficult
Mk I Inserter32042
Mk II Inserter103572

[back to top]